Kewalramani Reshma 4

What Happened Reshma Kewalramani, CEO, President and Director of Vertex Pharmaceuticals (VRTX), was granted 16,326 restricted stock units (RSUs) on Feb 17, 2026 and concurrently had 6,554 shares disposed to satisfy tax withholding obligations. The RSUs were recorded at $0.00 (award), and the withheld shares were disposed at $483.75 each for a reported total of $3,170,498. The RSU award vests in installments beginning Feb 20, 2027 (see footnote).

Key Details

• Transaction date: 2026-02-17; Form 4 filed: 2026-02-19 (within the standard two-business-day reporting window).
• Award: 16,326 RSUs granted (acquisition code A) at $0.00.
• Tax withholding sale: 6,554 shares disposed (code F) at $483.75 per share for $3,170,498.
• Shares owned after the transaction: not disclosed in the provided filing excerpt.
• Footnote: F1 — RSU award vests in installments beginning February 20, 2027.
• Nature of transactions: RSU grant (award) and share disposition for tax withholding (not an open-market sell driven by investment view).

Context RSU grants are compensation awards (no cash purchase) and typically vest over time; the footnote indicates vesting starts Feb 20, 2027. The disposal of 6,554 shares was to cover tax withholding — a routine administrative transaction that does not necessarily reflect a change in the insider’s market view. The award increases potential future ownership as it vests; the withholding reduces current share count to meet tax obligations.